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Abstract
Despite being considered a tropical disease, visceral leishmaniasis (VL) caused by L. infantum is also endemic in the Mediter-
ranean Europe and represents an increasing cause of morbidity and mortality in solid organ transplant (SOT) recipients. VL 
occurring in kidney transplant recipients is a severe event, often worsening the renal damage and leading to poor outcome. 
It is believed that most of VL cases in transplant recipients are caused by reactivation of a pre-existent, dormant leishmanial 
infection induced by the immunosuppressive drugs. Nevertheless, the prevalence of asymptomatic Leishmania infection in 
candidates to kidney transplant residing in or visiting endemic areas is unknown. As L. infantum is highly circulating in north-
eastern Italy, we aimed to examine the occurrence of this parasitic infection in 119 dialysis patients living in the mentioned 
area, 71 of whom were potential candidates to kidney transplant. By employing a combination of sensitive serological and 
molecular methods, we observed a prevalence of 15.9% asymptomatic Leishmania infection in the study cohort. This finding 
emphasizes the need of further evaluating potential screening strategies for Leishmania infection in solid organ transplant 
candidates residing in or visiting endemic areas.
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Introduction
Leishmaniasis is a chronic infectious disease caused by pro-
tozoa of the genus Leishmania [1]. The parasites are spread 
through the bite of infected phlebotomine sand flies and 
mostly target reticuloendothelial cells. The clinical spectrum 
of disease depends on the parasite species and on the host 
immune response, varying from asymptomatic infection 
(80–95% of infected individuals) to three different clini-
cal manifestations (5–20% of cases): visceral leishmaniasis 
(VL), cutaneous leishmaniasis and mucosal or mucocu-
taneous leishmaniasis. VL is a severe disease caused by 
Leishmania species belonging to the Leishmania donovani 
complex; in the Mediterranean Europe, VL is caused by L. 
infantum. Immunosuppression may reactivate latent leish-
manial infection [2] and among HIV-infected patients the 
risk of clinical VL is increased by over 100 times. In recent 
years, an increase of VL cases has also been reported in solid 
organ transplant (SOT) recipients [3, 4].
Among immunocompromised patients, cutaneous and 
mucocutaneous leishmaniasis are rare, whereas VL is 
the dominant clinical presentation [4]. The prevalence 
of VL among SOT recipients is 0.05–0.9% in endemic 
areas [5] and more than 100 VL cases following trans-
plantation—mainly kidney transplant—have been reported 
worldwide up to 2017 [6]. The classic triad of fever, sple-
nomegaly, and pancytopenia only occur in one third of 
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SOT patients, leading to difficulties in diagnosis, in par-
ticular, splenomegaly is reported less frequently than in 
immunocompetent patients [4, 6]. In kidney transplant 
recipients, leishmaniasis often includes acute interstitial 
nephritis with moderate inflammation and infiltration of 
lymphocytes, plasma cells and macrophages and can lead 
to graft dysfunction [7]. Moreover, VL in SOT exhibits 
high relapse and mortality rates [2, 3]. The most common 
cause of death in immunocompromised patients with VL 
is the presence of concomitant bacterial, viral or fungal 
infections [4, 8].
Currently, screening of the candidates to SOT for Leish-
mania infection in endemic areas is not recommended [2, 
5, 9], but a strict monitoring is suggested in case a Leish-
mania-positive recipient is found for potential reactivation 
of this parasitic infection [6].
The aim of this study was to investigate the presence 
of clinically silent Leishmania infection in candidates to 
SOT. We analyzed the prevalence of asymptomatic Leish-
mania infection by serological and molecular tests in a 
cohort of patients with end stage renal disease (ESRD) 
undergoing dialysis treatment, most of whom were poten-
tial candidates to kidney transplant. The study was per-
formed in the Bologna province, northeastern Italy, which 
is an endemic area for human leishmaniasis [10].
Methods
Study population, setting, and samples
We conducted a retrospective study including a target 
population of ESRD adult patients in dialysis treatment. 
Inclusion criteria were: (1) absence of medical history of 
VL or cutaneous leishmaniasis, (2) lack of symptoms for 
VL or suspected lesions for cutaneous leishmaniasis at the 
time of blood sampling, (3) absence of other infectious 
diseases at the time of blood sampling, and (4) residence 
in the Bologna province. Among the 119 patients included 
for the study (92% Caucasians, 61.3% male, 38.7% female, 
mean age 70 years), 71 patients (60%) were potential can-
didates to kidney transplant. Serum and whole blood sam-
ples were collected from May to December 2016 at the 
Nephrology, Dialysis and Renal Transplantation Unit, St. 
Orsola-Malpighi University Hospital (Bologna, Italy) and 
stored at  − 80 °C until analysis. The samples were subse-
quently investigated for the presence of anti-Leishmania 
antibodies and leishmanial DNA. The study was conducted 
in accordance with the Declaration of Helsinki, and the 
protocol was approved by the Ethics Committee of the St. 
Orsola-Malpighi University Hospital (project identifica-
tion code: 97/2017/O/Tess).
Detection of anti‑Leishmania antibodies
The presence of specific anti-Leishmania IgG was assessed 
by Western Blot (WB). All sera were analyzed by a commer-
cially available Leishmania Western Blot IgG (LDBio Diag-
nostics®, Lyon, France) according to the manufacturer’s rec-
ommendations. WB technique provides detailed antibody 
responses to the leishmanial 14-kDa and 16-kDa proteins of 
L. infantum. The presence of specific antibody to p14 and/or 
p16 proteins was considered as a positive result [11].
Detection of parasitic DNA
A PCR assay based on kinetoplast (k)DNA amplification 
was developed for detection of Leishmania DNA in whole 
blood samples. Nucleic acids were extracted from 100 
µL whole blood with NucliSENSeasyMAG (Biomerieux, 
Marcy l’Etoile, France). DNA was eluted in 50 µL of elu-
tion buffer. DNA was amplified employing a PCR targeting 
leishmanial kinetoplast (k)DNA [12]. Primers (15 pmol of 
RV1 5′-CTT TTC TGG TCC TCC GGG TAGG-3′, 15 pmol of 
RV2 5′-CCA CCC GGC CCT ATT TTA CAC CAA -3′) were 
synthesized by PrimmBiotech (Milan, Italy) and 50 pmol 
of TaqMan probe (FAM-TTT TCG CAG AAC GCC CCT ACC 
CGC -TAMRA) were synthesized by IDTDNA (Leuven, 
Belgium). β2-microglobulin Real-time PCR assay was run 
simultaneously as a control of amplification of the extracted 
DNA. The Real-time PCR assays were performed using the 
Real Time PCR Cycler Rotor Gene 3000 (Qiagen, Hilden 
Germany). Real Time PCR was considered positive for 
Leishmania DNA when an amplification curve at threshold 
cycle (tC) below 40 was present.
Statistical analysis
Descriptive statistics were used to analyze demographic and 
clinical characteristics. Chi-squared test was used to analyze 
potential correlation between detection of Leishmania infec-
tion and gender. Significance was established at p < 0.05.
Results
We obtained clinical samples from 119 ESRD adult patients 
in dialysis treatment at the St.Orsola-Malpighi University 
Hospital (Bologna, Italy). Seventy-one out of 119 patients 
(60%) were potential candidates to kidney transplant. The 
age of patients ranged from 20 to 94 years, with a mean 
age of 70, with a male-to-female ratio of 73:46. Most of 
patients were Caucasian (92%), with a percentage of 2% 
of Asian, 5% of African and 1% of unknown origin. The 
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main causes of ESRD in the cohort of patients were diabetic 
nephropathy (28%) and hypertensive vascular nephropathy 
(18%). Twenty-three percent of patients had a nephropathy 
of unknown origin. Demographic and clinical data of the 
study cohort are reported in Table 1.
Nineteen out of 119 patients (15.9%) were positive at 
the serological and/or molecular test for Leishmania infec-
tion; the mean age of positive patients was 69 years and 
the male-to-female ratio was 14:5. There was no significant 
correlation between presence of asymptomatic Leishmania 
infection and gender (χ2 = 1.45, p value = 0.23). None of the 
Asian patients was positive for the parasitic infection, while 
33% of African patients and 15% of Caucasian patients were 
positive for at least one Leishmania test. Results of WB anal-
ysis showed the presence of specific antibody to 14 and/or 
16 kDa proteins, indicating the presence of anti-Leishmania 
IgG in 17 ESRD patients (14.3-95% CI 8—20.4%) (Table 2). 
In 3 patients’ sera, both bands were detected, while antibod-
ies against p14 or p16 were found in 13 and 1 serum sample, 
respectively. Circulating Leishmania kDNA was detected in 
peripheral blood from 3 out of 119 ESRD patients (2.5–95% 
CI 0.3–5.3%); only 1 patient showed simultaneous detection 
of anti-leishmanial IgG (WB reactivity to 14 kDa protein) 
and parasitic DNA in peripheral blood. None of the patients 
Table 1  Demographic variables 
and clinical data of patients 
with end stage renal disease
Percentages are calculated based on the total number for each column
a Pts; patients, bNo.; number
Total (119  ptsa) Nob of positive pts to 
Leishmania infection 
(19)
No. of negative pts to 
Leishmania infection 
(100)
Age, years (range)
 20–34 2 (2%) 1 (5%) 1 (1%)
 35–49 8 (7%) 0 (0%) 8 (8%)
 50–64 23 (19%) 5 (26%) 18 (18%)
 65–79 51 (43%) 7 (37%) 44 (44%)
  > 80 33 (28%) 6 (32%) 27 (27%)
 Unknown 2 (2%) 0 (0%) 2 (2%)
 Mean age, years 70 69 79
Gender
 Female 46 (39%) 5 (26%) 41 (41%)
 Male 73 (61%) 14 (74%) 59 (59%)
Origin
 Caucasian 110 (92%) 17 (89%) 93 (93%)
 Asian 2 (2%) 0 (0%) 2 (2%)
 African 6 (5%) 2 (11%) 4 (4%)
 Unknown 1 (1%) 0 (0%) 1 (1%)
Cause of ESRD
 Diabetic nephropathy 33(28%) 4 (21%) 29 (29%)
 Glomerular disease 13 (11%) 2 (11%) 11 (11%)
 Hypertensive vascular nephropathy 21 (18%) 6 (32%) 15 (15%)
 Interstitial disease 16 (13%) 1 (5%) 15 (15%)
 Polycystic kidney disease 9 (8%) 1 (5%) 8 (8%)
 Unknown 27 (23%) 5 (26%) 22 (22%)
Dialysis vintage, years (range)
 0–3 47 (39%) 10 (53%) 37 (37%)
 4–7 35 (29%) 4 (21%) 31 (31%)
 7–10 17 (14%) 2 (11%) 15 (15%)
  > 10 20 (17%) 3 (16%) 17 (17%)
Table 2  Western Blot and Real Time PCR to detect asympto-
matic Leishmania infection in patients with end stage renal disease 
(n = 119)
WB; Western Blot. PCR; polymerase chain reaction. Pos; positive. 
Neg; negative. No; number
WB Pos WB Neg PCR Pos PCR Neg
No. (%) No. (%) No. (%) No. (%)
17 (14.3) 102 (85.7) 3 (2.5) 116 (97.5)
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testing positive to anti-leishmanial antibody and/or parasitic 
DNA showed signs or symptoms compatible with VL or 
tegumentary leishmaniasis.
Discussion
To our knowledge, there are no studies on the prevalence 
of asymptomatic Leishmania infection in kidney transplant 
candidates. Here, we detected the presence of clinically 
silent Leishmania infection in 15.9% of ESRD patients in 
dialysis treatment. As 60% of these patients were potential 
recipients for kidney transplant, this study group might be 
considered as a model for candidates to SOT.
Leishmania-specific antibodies were revealed by WB in 
serum samples obtained from 17 patients, which showed 
antibody to 14 and/or 16 kDa proteins, while parasitic DNA 
was detected in blood samples of 3 patients by kDNA ampli-
fication. Overall, our results suggest an important cumu-
lative exposure to Leishmania in the examined cohort, 
which may potentially lead to parasitic reactivation upon 
transplantation.
A recent study from southern Spain showed a prevalence 
of 4.8% of asymptomatic Leishmania infection in renal 
transplant recipients [13]; differently from this study, we 
enrolled dialyzed patients who did not receive immunosup-
pressive drugs. The lower prevalence of Leishmania infec-
tion observed in the Spanish study as compared to our study 
can be related to a variable circulation of the parasite in 
different endemic areas or to diversity of methods employed 
for parasite screening. Considering the latter possibility, 
the indirect immunofluorescence assay (IFAT) employed 
by Elmahallawy and colleagues could have underestimated 
the infection rate in asymptomatic carriers. In fact, evidence 
indicates that IFAT exhibits a lower sensitivity than WB 
and sera from VL patients recognize the 14–16-kD bands in 
WB at concentrations  107 lower than the threshold values of 
IFAT [11]. As using a combination of tests has been reported 
to increase the capacity to detect asymptomatic Leishmania 
infection [1], we employed the most sensitive serological 
method, namely WB [9, 11, 14] together with a molecular 
test.
Leishmania infection may be transmitted to transplant 
recipients by different ways, including the donor allograft, 
the transfusion of blood products, a de novo posttransplant 
infection or through reactivation of pretransplant infection, 
the latter generally considered the most common route of 
infection [2, 15]. Nevertheless, studies focusing on para-
site route of transmission in SOT are lacking. In addition, 
there is no consensus recommendation to screen the organ 
transplant recipients for Leishmania infection in endemic 
areas [2, 5, 9]. Furthermore, different methods are avail-
able to detect asymptomatic Leishmania infection, including 
serology, molecular tests and ex vivo whole blood stimula-
tion with parasitic antigens combined with specific cytokine 
release assay [1, 16], but no gold standard method has been 
defined so far [5, 17]. On the other hand, updated guidelines 
recommend that those known to be Leishmania-seropositive 
at the time of transplant should be monitored closely for 
potential reactivation of the parasitic infection [5].
Considering the high prevalence of Leishmania infec-
tion among potential kidney transplant recipients detected 
in the current study, we emphasize the importance of further 
evaluating sensitive tools for screening this hemoflagellate 
protozoan in SOT candidates in endemic areas.
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